Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy (Q50879633)

From Wikidata

Jump to navigation Jump to search

scientific article published on 25 June 2013

Language	Label	Description	Also known as
English	Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy	scientific article published on 25 June 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23799935

Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23799935

0 references

1 reference

based on heuristic

inferred from title

Karl-Christian Bergmann

6

object named as

Karl-Christian Bergmann

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

8

object named as

Ulrich Wahn

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23799935

Eckard Hamelmann

2

object named as

Eckard Hamelmann

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23799935

author name string

Matthias Volkmar Kopp

1

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23799935

Meike Bendiks

3

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23799935

Stefan Zielen

4

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23799935

Wolfgang Kamin

5

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23799935

Christian Klein

7

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23799935

DUAL study group

9

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23799935

publication date

25 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23799935

Pediatric Allergy & Immunology

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23799935

24

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23799935

5

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23799935

427-433

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23799935

Targeting IgE with monoclonal antibodies: the future is now.

1 reference

https://api.crossref.org/works/10.1111%2FPAI.12098

21 January 2018

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FPAI.12098

21 January 2018

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

1 reference

https://api.crossref.org/works/10.1111%2FPAI.12098

21 January 2018

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

1 reference

https://api.crossref.org/works/10.1111%2FPAI.12098

21 January 2018

Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma

1 reference

https://api.crossref.org/works/10.1111%2FPAI.12098

21 January 2018

Role of immunmodulators in allergen-specific immunotherapy

1 reference

https://api.crossref.org/works/10.1111%2FPAI.12098

21 January 2018

Omalizumab: Anti-IgE therapy in allergy

1 reference

https://api.crossref.org/works/10.1111%2FPAI.12098

21 January 2018

Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.

1 reference

https://api.crossref.org/works/10.1111%2FPAI.12098

21 January 2018

Omalizumab and the risk of malignancy: results from a pooled analysis

1 reference

https://api.crossref.org/works/10.1111%2FPAI.12098

21 January 2018

Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study

1 reference

https://api.crossref.org/works/10.1111%2FPAI.12098

21 January 2018

Identifiers

10.1111/PAI.12098

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23799935

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/23799935

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50879633&oldid=2262471310"